Our goal is for NanoViricides, Inc. to be the leading company bringing the advantages of the nanomedicine approach to the anti-viral therapy platform.
With the concerted multiple targeted set of mechanisms we have listed, our objective is for a nanoviricide to be programmed to (a) prevent the virus particle from being able to infect new cells, (b) dismantle the virus particle, and (c) destroy the genetic material (for example, the RNA of influenza virus, or the DNA of herpes simplex virus) and/or "essential cargo" of the virus particle (such as the reverse transcriptase associated with the HIV virion), thereby completely destroying the "enemy". This "Systems-Engineered" approach to anti-viral therapy is in stark contrast with the current piece-meal approaches that lead to extensive toxicities, limited efficacies, and virus mutataions due to incomplete selective pressure applied by the therapeutic regime onto the virus.
The mechanism of action of a nanoviricide in practice is expected to be rather complex. The description we are providing here is only a simplified explanation intended to give a glimpse of the possible events to a casual reader, and is not intended as a scientifically accurate documentation of the mechanism of action.
